Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 09, 2021

Incretin–Based Therapies vs SGLT-2 Inhibitors and COVID-19 Outcomes in Diabetes Patients

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Comparable COVID-19 Outcomes With Current Use of GLP-1 Receptor Agonists, DPP-4 Inhibitors or SGLT-2 Inhibitors Among Patients With Diabetes Who Tested Positive for SARS-CoV-2
Diabetes Obes Metab 2021 Jan 27;[EPub Ahead of Print], S Bastrup Israelsen, A Pottegård, H Sandholdt, S Madsbad, RW Thomsen, T Benfield

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading